United States: FTC Issues Updated Media Guidance For Screening Fake Weight Loss Claims

On January 7, 2014, the Federal Trade Commission announced "Operation Failed Resolution", targeting false and deceptive claims made by marketers of weight loss products.  As part of this initiative, the FTC issued updated guidance for use by the media to help them spot phony weight-loss claims when screening ads for publication.  Along with the release of this media guidance, the FTC also announced the settlement of four enforcement actions against companies marketing foods, cosmetics or dietary supplements.  In connection with these weight-loss and similar cases, there appears to be disagreement among the Commissioners as to a substantiation rule that would require two "randomized controlled trials" to substantiate health and disease-related claims.


The FTC filed a complaint against Sensa for marketing its product as a food that you could "sprinkle on [your food] to take the weight off."  Sensa represented that clinical studies supported the weight losses claimed.  However, according to the FTC, the company did not have the science to back up these claims.  Alleged deficiencies in the clinical studies include lack of blinding, the lack of a placebo control, failure to account for subjects that do not complete the study, and failure to monitor the subjects' diet and exercise (weights were self-reported).  In addition, Sensa allegedly failed to disclose that its consumer endorsers had been offered compensation in exchange for their endorsement.  According to the complaint, sales of Sensa in the United States totaled nearly $364 million for the period from 2008-2012.  Sensa agreed to pay 26.5 million dollars into a fund to be used for consumer redress.


The FTC alleged that L'Occitane marketed certain skin cream products as "cellulite fighters" with claims that they "visibly reduce the appearance of cellulite" and "trim 1.3 inches in just 4 weeks" off thighs.  L'Occitane claimed that it had clinical evidence to support these claims.  However, the FTC alleged that the clinical evidence failed to substantiate the claims.  According to the FTC, the evidence relied on consisted primarily of results from a single unblended, uncontrolled clinical trial and L'Occitane exaggerated the results of the trial.  According to the FTC's complaint, the average reported reduction in thigh circumference was less than a quarter of an inch, and only one participant (out of fifty) reportedly achieved a reduction of 1.3 inches.

L'Occitane agreed to pay $450,000 pursuant to the FTC settlement into a fund to be used for consumer redress.

HCG Diet Direct

The third settlement announced involved HCG's Diet Direct product.  Allegedly, the company marketed Diet Direct as a  homeopathic weight-loss product.  Diet Direct purportedly contained human chorionic gonadotropin; and HCG claimed that consumers could lose as much as a pound a day merely by putting drops under the tongue before meals.  The FTC alleged that the weight loss claims touting Diet Direct were either false or unsubstantiated.  Additionally, the FTC alleged that HCG failed to disclose that certain of the people providing testimonials in Diet Direct ads were compensated for their endorsements or were relatives of company representatives.

LeanSpa, LLC

The FTC's fourth settlement involves LeanSpa, LLC, and other related companies.  LeanSpa allegedly deceptively promoted acai berry and "colon cleanse" weight-loss supplements marketed under various brand names through fake news websites.  According to the FTC, among other allegedly deceptive practices, the marketers used domain names that appeared to be objective news or health websites (e.g., "channel8health.com") and aired reports that were falsely represented to have aired on major broadcast and cable networks.  The reports were authored by purported testers of the LeanSpa products who reported dramatic and positive results.

The FTC reached a settlement pursuant to which, in addition to a variety of injunctive relief, the respondents surrendered assets worth approximately $7 million.

Updated guidance for media outlets on spotting bogus weight-loss claims in advertising

As part of its initiative, the FTC also issued an updated guidance for media to recognize bogus weight loss claims, "Gut Check."  This guidance instructs media outlets on how to screen advertisements for facially deceptive weight loss claims, so that they will refuse to publish or to air deceptive ads.  Although the FTC has the authority to sue media outlets for running deceptive ads, statements made at the FTC's press conference announcing this guidance indicate that the FTC does not intend to pursue action against media outlets.  Instead, the guidance appears designed to encourage the media's voluntary cooperation.  The updated guidance includes tips on testimonials and an online tutorial.  It also identifies seven representations believed to be inherently deceptive and the media should avoid airing.  These "Gut Check" claims are claims that a product:

  1. causes weight loss of two pounds or more a week for a month or more without diet or exercise;
  2. causes substantial weight loss no matter what or how much the consumer eats;
  3. causes permanent weight loss even after the consumer stops using the product;
  4. blocks the absorption of fat or calories to enable consumers to lose substantial weight;
  5. safely enables consumers to lose more than three pounds a week for more than four weeks;
  6. causes substantial weight loss for all users; and
  7. causes substantial weight loss by wearing a product on the body or rubbing it into the skin.

As part of this campaign, the FTC will send guidance letters to 75 media outlets to assist them in recognizing bogus weight loss claims.

Commissioners question the "standard" requirements for two randomized clinical trials

On the same day that the FTC announced the settlements in the weight loss cases, it also announced a settlement against GeneLink concerning the advertising of a customized dietary supplements to treat diseases.

The weight-loss and Genelink settlements define "competent and reliable evidence" for the relevant products as requiring two well-controlled human clinical studies (randomized controlled trials or RCT's).  However, there appears to be disagreement within the Commission about whether this high standard is justified under all circumstances.  Notably, Commissioners Ohlhausen and Wright issued separate statements in which they, among other things, raise questions regarding the requirement for two RCT's to satisfy the standard of "competent and reliable scientific evidence" for other than weight loss claims.  Commissioner Wright states that "t]he optimal amount and type of evidence to substantiate a future claim will vary from case to case," and urges the Commission to consider whether this requirement "strikes the right balance between deterring deceptive advertising and preserving the consumers the benefits of truthful claims. Commissioner Ohlhausen similarly expresses concern that the requirement of 2 RCTs has become a "standard requirement for health-and disease-related claims for a wide array of products," cautioning that "[a]dopting a one-size-fits-all approach to substantiation by imposing such rigorous and possibly costly requirements for ...a broad category of health-and disease-related claims may, in many instances, prevent useful information from reaching consumers in the marketplace and ultimately make consumers worse off."  She advocates a carful application of the factors enunciated Pfizer, Inc.,  81 F.T.C. 23 (1972), rather than requiring two RCTs without consideration of the particular circumstances in the case at issue.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
31 Jan 2019, Other, Los Angeles, United States

Invites you to join us for a private cooking class hosted by Parties that Cook!

31 Jan 2019, Conference, Los Angeles, United States

The Southern California Association of Corporate Counsel's In-House Counsel Conference

6 Feb 2019, Other, Los Angeles, United States

Please join Sheppard Mullin for cocktails & hors d'oeuvres during The Wind Power Finance & Investment Summit 2019

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions